Compare · ABT vs SNOA
ABT vs SNOA
Side-by-side comparison of Abbott Laboratories (ABT) and Sonoma Pharmaceuticals Inc. (SNOA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and SNOA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $179.51B, about 32902.7x SNOA ($5.5M).
- Over the past year, ABT is down 18.4% and SNOA is down 66.6% - ABT leads by 48.2 points.
- SNOA has been more active in the news (8 items in the past 4 weeks vs 2 for ABT).
- ABT has more recent analyst coverage (25 ratings vs 0 for SNOA).
- Company
- Abbott Laboratories
- Sonoma Pharmaceuticals Inc.
- Price
- $103.11+2.27%
- $1.11-3.48%
- Market cap
- $179.51B
- $5.5M
- 1M return
- +13.92%
- -5.53%
- 1Y return
- -18.37%
- -66.57%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2007
- News (4w)
- 2
- 8
- Recent ratings
- 25
- 0
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Sonoma Pharmaceuticals Inc.
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for various applications, including wound care, animal health care, eye care, oral care, and dermatological conditions in the United States and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a product indicated to promote healing through the management of new and old scars; and SebuDerm to manage and relieve the burning, itching, pain, and distraction associated with seborrhea and seborrheic dermatitis. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a line of products to stimulate expedited healing by targeting various pathogens, as well as antibiotic-resistant strains that slow natural healing of wounds. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; Microdacyn60 oral care solution for the treatment of mouth and throat infections; Lasercyn gel intended for the management of minor skin irritations; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; Pediacyn atopic dermatitis hydrogel; Gramaderm for the treatment of topical mild to moderate acne; Microsafe, a surface disinfectant; and Sinudox for nasal irrigation, including moistening of cuts, abrasions, and lacerations located in the nasal cavity. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia.
Latest ABT
- Abbott Laboratories filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
- SEC Form 4 filed by Director Stratton John G
- SEC Form 4 filed by Director Roman Michael F
- SEC Form 4 filed by Director Gonzalez Patricia Paola
- SEC Form 4 filed by Director Conroy Kevin T
- SEC Form 4 filed by Director Ahuja Nita
- EXECUTIVE VICE PRESIDENT Morrone Louis H. covered exercise/tax liability with 269 units of Common shares without par value, decreasing direct ownership by 0.35% to 76,574 units (SEC Form 4)
- Robert W. Baird initiated coverage on Abbott Labs with a new price target
- EVP, GC AND SECRETARY Cushman Elizabeth C. covered exercise/tax liability with 560 units of Common shares without par value, decreasing direct ownership by 1% to 38,013 units (SEC Form 4)
Latest SNOA
- SEC Form DEFA14A filed by Sonoma Pharmaceuticals Inc.
- SEC Form 4 filed by Director Weigerstorfer Philippe
- SEC Form 4 filed by Chief Executive Officer Trombly Amy Moss
- SEC Form 4 filed by Director Mclaughlin John
- SEC Form 4 filed by Director Jacoby Vanessa
- SEC Form 4 filed by Chief Financial Officer Dvonch Jerome J
- SEC Form 4 filed by Controller Dal Poggetto John
- SEC Form S-8 filed by Sonoma Pharmaceuticals Inc.
- Sonoma Pharmaceuticals Receives FDA 510(k) Clearance Expanding Indications and Packaging Options for Microdacyn(R) Wound Irrigation Solution
- SEC Form DEFA14A filed by Sonoma Pharmaceuticals Inc.